Cellular exposure to ionizing radiation (IR) activates a series of molecular signaling pathways, leading to cell cycle arrest, DMA repair, and/or apoptosis. Each signaling pathway has a characteristic molecular signature, defined by activated (phosphorylated) target proteins, and protein assembly in radiation-inducible nuclear foci. These convenient molecular signatures (biomarkers) can now be exploited in the development of diagnostic and therapeutic medical applications for human radiation exposure.
In specific Aim 1, we will examine biomarkers in one radiation damage-response pathway (the Fanconi Anemia Pathway), to generate, test, and calibrate a biodosimeter in mouse and human models. We will obtain peripheral blood lymphocytes from human cancer patients undergoing Total Body Irradiation in order to test the sensitivity and specificity of the biodosimeter.
In Specific Aim 2, we will conduct pathway-specific and general cell-based, small molecule drug screens, in order to identify novel radioprotective agents. Agents will be tested in murine and bone marrow progenitor assays for their cytoprotective effect.
In specific aim 3, we will analyze a novel Reactive Oxygen Species (ROS) scavenger, WW-85, in murine and human radiation protection assays. We will test the ability of WW-85 to improve survival in the murine radiation LD50 model, lessen radiation-induced tissue damage, and improve the clonigenic survival of murine bone marrow stem cells. The work will be fortified by numerous interactions with the other projects (Livingston, Elledge, Sicinski) and with the Mouse Biology and Stem Cell Core (Core B), the Institute for Chemistry and Chemical Screening Core (Core C), and the Radiation Clinical Trial Core.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI067751-05
Application #
7923837
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
5
Fiscal Year
2009
Total Cost
$192,468
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Beemelmanns, Christine; Ramadhar, Timothy R; Kim, Ki Hyun et al. (2017) Macrotermycins A-D, Glycosylated Macrolactams from a Termite-Associated Amycolatopsis sp. M39. Org Lett 19:1000-1003
Guinan, Eva C; Palmer, Christine D; Mancuso, Christy J et al. (2014) Identification of single nucleotide polymorphisms in hematopoietic cell transplant patients affecting early recognition of, and response to, endotoxin. Innate Immun 20:697-711
Guinan, Eva C; Barbon, Christine M; Kalish, Leslie A et al. (2011) Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med 3:110ra118
D'Andrea, Alan D (2010) Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 362:1909-19
Parmar, Kalindi; Kim, Jungmin; Sykes, Stephen M et al. (2010) Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells 28:1186-95
Tolopko, Andrew N; Sullivan, John P; Erickson, Sean D et al. (2010) Screensaver: an open source lab information management system (LIMS) for high throughput screening facilities. BMC Bioinformatics 11:260
Parmar, Kalindi; D'Andrea, Alan; Niedernhofer, Laura J (2009) Mouse models of Fanconi anemia. Mutat Res 668:133-40
Sun, Yingli; Jiang, Xiaofeng; Xu, Ye et al. (2009) Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol 11:1376-82
Moldovan, George-Lucian; D'Andrea, Alan D (2009) FANCD2 hurdles the DNA interstrand crosslink. Cell 139:1222-4
Kim, Jung Min; Parmar, Kalindi; Huang, Min et al. (2009) Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell 16:314-20

Showing the most recent 10 out of 19 publications